

# A W Armstrong

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7211989/a-w-armstrong-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

121  
papers

5,114  
citations

32  
h-index

71  
g-index

145  
ext. papers

6,576  
ext. citations

5.3  
avg, IF

6.29  
L-index

#	Paper	IF	Citations
121	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1318-28	59.2	530
120	Psoriasis prevalence among adults in the United States. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 512-6	4.5	518
119	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled LYOMAGE 2 trial. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 1118-131	4.5	405
118	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 422-34	59.2	324
117	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1029-1072	4.5	296
116	The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. <i>Nutrition and Diabetes</i> , <b>2012</b> , 2, e54	4.7	281
115	Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 1945-1960	27.4	268
114	Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. <i>JAMA Dermatology</i> , <b>2013</b> , 149, 1180-5	5.1	238
113	Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. <i>PLoS ONE</i> , <b>2012</b> , 7, e52935	3.7	177
112	Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. <i>Drugs</i> , <b>2014</b> , 74, 423-41	12.1	158
111	Economic Burden of Psoriasis in the United States: A Systematic Review. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 651-8	5.1	144
110	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. <i>Lancet, The</i> , <b>2019</b> , 394, 831-839	40	141
109	US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>American Journal of Clinical Dermatology</i> , <b>2016</b> , 17, 87-97	7.1	121
108	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 290-298	4.5	90
107	Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011. <i>Dermatology</i> , <b>2012</b> , 225, 121-6	4.4	67
106	Psoriasis and suicidality: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 425-440.e2	4.5	59
105	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , <b>2021</b> , 397, 487-498	40	51

104	Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 432-8	5.1	49
103	Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , <b>2019</b> , 9, 5-18	4	44
102	Teledermatology in the United States: An Update in a Dynamic Era. <i>Telemedicine Journal and E-Health</i> , <b>2018</b> , 24, 691-697	5.9	43
101	Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 2437-2446.e1	4.3	42
100	Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis. <i>F1000Research</i> , <b>2014</b> , 3, 248	3.6	40
99	Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, 1940-1949	4.6	39
98	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 936-945	4.5	38
97	Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 968-77.e2	4.5	37
96	Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. <i>JAMA Dermatology</i> , <b>2016</b> , 152, 661-9	5.1	37
95	Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. <i>Rheumatology International</i> , <b>2017</b> , 37, 97-105	3.6	36
94	Patient-centered, direct-access online care for management of atopic dermatitis: a randomized clinical trial. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 154-60	5.1	36
93	Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 1093-1104	5.3	35
92	Association Between Atopic Dermatitis and Suicidality: A Systematic Review and Meta-analysis. <i>JAMA Dermatology</i> , <b>2019</b> , 155, 178-187	5.1	34
91	Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data. <i>Dermatology and Therapy</i> , <b>2017</b> , 7, 97-109	4	33
90	Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 665-669	4.5	33
89	The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 345-8	4.5	31
88	Fate of manuscripts declined by the Journal of the American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 632-5	4.5	31
87	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 1704-1716	4.5	31

86	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , <b>2020</b> , 10, 133-150	4	29
85	Bimekizumab versus Adalimumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 130-144	4.2	28
84	A review of health outcomes in patients with psoriasis. <i>Dermatologic Clinics</i> , <b>2012</b> , 30, 61-72, viii	4.2	26
83	Set-back versus buried vertical mattress suturing: results of a randomized blinded trial. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 674-80	4.5	25
82	Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. <i>JAMA Dermatology</i> , <b>2018</b> , 154, 1137-1144	4.4	24
81	Dermatologists in social media: A study on top influencers, posts, and user engagement. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 1452-1455	4.5	22
80	Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, 2200-2207	4.6	22
79	Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , <b>2016</b> , 9, S12-S16	1.2	21
78	Epidemiology of classic and AIDS-related Kaposi's sarcoma in the USA: incidence, survival, and geographical distribution from 1975 to 2005. <i>Epidemiology and Infection</i> , <b>2013</b> , 141, 200-6	4.3	19
77	Effect of Adhesive Strips and Dermal Sutures vs Dermal Sutures Only on Wound Closure: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 862-7	5.1	17
76	Public perception of dermatologists and comparison with other medical specialties: results from a national survey. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 875-81	4.5	17
75	The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1227-9	4.1	16
74	Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 306-314	4	16
73	Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. <i>BMC Dermatology</i> , <b>2018</b> , 18, 4	2.1	14
72	Direct-Access Online Care for the Management of Atopic Dermatitis: A Randomized Clinical Trial Examining Patient Quality of Life. <i>Telemedicine Journal and E-Health</i> , <b>2017</b> , 23, 726-732	5.9	13
71	Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210517	3.7	12
70	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 1733-1741	4.6	12
69	Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2016</b> , 20, 196-206	1.6	12

68	Psoriasis provoked or exacerbated by medications: identifying culprit drugs. <i>JAMA Dermatology</i> , <b>2014</b> , 150, 963	5.1	12
67	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , <b>2020</b> , 21, 881-890	7.1	12
66	Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , <b>2019</b> , 30, 454-460	2.8	12
65	Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation. <i>Archives of Dermatological Research</i> , <b>2013</b> , 305, 891-7	3.3	11
64	Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial. <i>Journal of Dermatological Treatment</i> , <b>2019</b> , 30, 27-34	2.8	10
63	Engaging but inaccurate: A cross-sectional analysis of acne videos on social media from non-health care sources. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 610-612	4.5	10
62	POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 795-1-796	2.4	8
61	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. <i>British Journal of Dermatology</i> , <b>2021</b> ,	4	8
60	Effects of Online Care on Functional and Psychological Outcomes in Patients with Psoriasis: A Randomized Controlled Trial. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> ,	4.5	7
59	Effect of Automated Online Counseling on Clinical Outcomes and Quality of Life Among Adolescents With Acne Vulgaris: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 970-5	5.1	7
58	Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. <i>Dermatology</i> , <b>2018</b> , 234, 157-165	4.4	7
57	Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: a population-based study. <i>Journal of Dermatological Treatment</i> , <b>2019</b> , 30, 135-140	2.8	7
56	Psoriasis and psoriatic arthritis educational initiatives: an update from the 2013 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1240-3	4.1	7
55	International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 959-60	4.1	7
54	The Use of Biologics During the COVID-19 Pandemic. <i>Dermatologic Clinics</i> , <b>2021</b> , 39, 545-553	4.2	7
53	Updates in Rosacea: Epidemiology, Risk Factors, and Management Strategies. <i>Current Dermatology Reports</i> , <b>2014</b> , 3, 23-28	1.5	6
52	Electroabrasion vs. manual dermabrasion: a randomized, double-blind, comparative effectiveness trial. <i>British Journal of Dermatology</i> , <b>2014</b> , 171, 124-9	4	6
51	Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 701-702	4.1	5

50	Effectiveness of a novel interactive health care education tool on clinical outcomes and quality of life in acne patients: A randomized controlled pilot study. <i>Journal of Dermatological Treatment</i> , <b>2015</b> , 26, 435-9	2.8	5
49	Outcomes research in psoriasis and psoriatic arthritis using large databases and research networks: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1233-6	4.1	5
48	Where you live matters: Regional differences in health care resource use for psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 1360-1367	4.5	5
47	Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , <b>2021</b> , 237, 151-157	4.4	4
46	Association between atopic dermatitis and conjunctivitis in adults: a population-based study in the United States. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 32, 455-459	2.8	4
45	A provider global assessment quality measure for clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 823-828	4.5	3
44	Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-9	2.8	3
43	Follicular eruption on arms and legs. Phrynoderma. <i>Archives of Dermatology</i> , <b>2008</b> , 144, 1509-14		3
42	Suicidality among psoriasis patients: a critical evidence synthesis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , <b>2019</b> , 154, 56-63	0.8	3
41	Does location matter? Geographic variations in healthcare resource use for atopic dermatitis in the United States. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 32, 314-320	2.8	3
40	Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy. <i>Archives of Dermatological Research</i> , <b>2019</b> , 311, 453-460	3.3	2
39	Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics. <i>Dermatology and Therapy</i> , <b>2020</b> , 10, 615-621	4	2
38	Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-6	2.8	2
37	THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19		2
36	Strategies to maximize clinical efficiency while maintaining patient safety during the COVID-19 pandemic: an interview-based study from private practice dermatologists. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-4	2.8	2
35	Assessing Skin Biopsy Rates for Histologic Findings Indicative of Nonpathological Cutaneous Disease. <i>Dermatologic Surgery</i> , <b>2019</b> , 45, 640-649	1.7	2
34	Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 31, 452-459	2.8	2
33	An association between hidradenitis suppurativa and HIV. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 490-491		2

32	Words matter: a randomized controlled study evaluating the impact of decision-framing on treatment preferences in adults with psoriasis and psoriatic arthritis. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 971-973	4	2
31	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 1-8	2.8	2
30	Association Between the Mental Health of Patients With Psoriasis and Their Satisfaction With Physicians. <i>JAMA Dermatology</i> , <b>2020</b> , 156, 754-762	5.1	1
29	Reply to Letter to the Editor Regarding: "Dermatologists in Social Media: A Study on Top Influencers, Posts, and User Engagement". <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> ,	4.5	1
28	Defining drug-free remission of skin disease in patients with plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 1484-1487	4	1
27	Report from the International Dermatology Outcome Measures Initiative. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , <b>2020</b> , 20, S80-S83	1.1	1
26	Language proficiency and biologics access: a population study of psoriasis patients in the United States. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-5	2.8	1
25	Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 31, 617-623	2.8	1
24	Response to Letter to the Editor "Reply to "Dermatologists in Social Media: A Study on Top Influencers, Posts, and User Engagement": Dermatologist Influencers on TikTok". <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> ,	4.5	1
23	Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost-effective. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35 Suppl 1, 28-34	4.6	1
22	Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , <b>2018</b> , 234, 112-119	4.4	1
21	Differences in health care resource utilization and costs for keratinocyte carcinoma among racioethnic groups: A population-based study. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> ,	4.5	1
20	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. <i>Dermatology</i> , <b>2021</b> , 1-8	4.4	1
19	Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic. <i>Dermatology Online Journal</i> , <b>2020</b> , 26,	1	1
18	Rosacea videos on social media: A comparison of accuracy, quality, and viewer engagement. <i>Dermatology Online Journal</i> , <b>2021</b> , 27,	1	1
17	Economic Burden of Chronic Hand Eczema: A Review.. <i>American Journal of Clinical Dermatology</i> , <b>2022</b> , 1	7.1	1
16	Screening Recommendations for Chlamydia and Gonorrhea. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 1014-6	5.1	0
15	Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. <i>American Journal of Clinical Dermatology</i> , <b>2020</b> , 21, 323-338	7.1	0

14	Topical opioid use in dermatologic disease: A systematic review. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e151502.2		o
13	Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 2147-2157	4	o
12	Who sees you matters: a population study examining topical corticosteroid prescribing patterns between primary care providers and dermatologists for atopic dermatitis. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-4	2.8	o
11	Exploring Mental Disorders in Patients With Skin Diseases. <i>JAMA Dermatology</i> , <b>2019</b> , 155, 660-661	5.1	
10	Re-Classification of Psoriasis Severity: Perspectives and Controversy. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2022</b> , 7, 7-8	1.1	
9	Pemphigus and bullous pemphigoid in the United States: a 21-year analysis of patient characteristics, treatment patterns, and comorbidities. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 1-3	2.8	
8	Childhood atopic dermatitis: outpatient visit trends, demographics, and topical agents in the United States, 1995-2015. <i>International Journal of Dermatology</i> , <b>2021</b> , 60, e423-e424	1.7	
7	AB0528 COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1293-1294	2.4	
6	Response to Letter to the Editor commenting on: "Dermatologists in social media: A study on top influencers, posts, and user engagement". <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, e165	4.5	
5	Differences in wage earnings between psoriasis patients on biologics versus those on oral therapies: a population-based study in the United States. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 32, 440-445	2.8	
4	Chronic spontaneous urticaria in the United States: patient characteristics and treatment patterns. <i>International Journal of Dermatology</i> , <b>2021</b> ,	1.7	
3	A Blueprint for the Conduct of Large, Multisite Trials in Telemedicine. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e29511	7.6	
2	Validation of Patient-Reported Psoriasis Diagnosis from a Global Online Research Network. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 2539-2541	4.3	
1	An unusual spiculated presentation of follicular porokeratosis. <i>Dermatology Online Journal</i> , <b>2019</b> , 25,	1	